Evidence map›Paper›PMID 40211223›Full record

ArticleBMC cancer2025

Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids.

Yan Lei, Chengsong Cao, Rui Tang, Yong Liu

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yan Lei *Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Chengsong Cao *Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Rui TangSchool of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Yong LiuDepartment of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China. lyly.7011@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe study aimed to assess the value of pretreatment peripheral blood neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and systemic immune-inflammation index/albumin ratio (SII/ALB) for predicting immunotherapy prognosis and efficacy in Non-small cell lung carcinoma (NSCLC) treated with Immune checkpoint inhibitors (ICIs) and opioids.

methodsA total of 78 NSCLC patients received ICIs and opioids were retrospectively collected. The optimal cut-off values were determined by receiver operating characteristic curves. The univariate and multivariate analysis investigated the effects of NLR, PLR, and SII/ALB on patients prognosis.

resultsNLR and PLR had predictive value of efficacy. SII/ALB > 17.79 was an independent risk factor for worse outcomes.

conclusionPLR and SII/ALB have predictive value of efficacy, but NLR was not. SII/ALB > 17.79 suggests a poor prognosis following immunotherapy in NSCLC patients receiving ICIs and opioids.

Indexed as

Analgesics, OpioidBlood PlateletsCarcinoma, Non-Small-Cell LungLung NeoplasmsLymphocytesNeutrophilsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmune Checkpoint InhibitorsImmunotherapyInflammationLymphocyte CountAnalgesics, OpioidBiomarkers, TumorImmune Checkpoint InhibitorsCancer painImmune checkpoint inhibitorsNon-small cell lung cancerOpioidsPeripheral blood inflammatory markerPrognostic value

Identifiers

PMID40211223
PMCPMC11987169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.